Yusuf Cem KAPLAN, Hakan ASLAN, Hüseyin ERTAŞ, İsmail Davut ÇAPAR, Elif TARIM ERTAŞ, Gökhan SAYGILI

KARDİYOVASRÜLER SİSTEM HASTALIKLARINDA KULLANILAN llıâÇLA'R ILF. ENDDDHNTII'IE SIS— TEMIK OLARAK KULLANILAN İLAÇLAR ARASINDAKİ İLAÇ ETKİLILŞİMLEILİ

Endodontik tedavi süresince kardiyovaskü-- ler." sisleııi ı'alıaLsızlLğı Lıuluııaıı haritalama çeşitli ilaçlar reçete edilebilmektedir. Bu gibi durumlarda eı'ıdodcıntide sistemik olarak kullanılan ilaçlar ile kardiyovasküler hastalığa bağlı olarak reçete ecli-- leıı ilaçlar knmbiııe olarak kııllaııılıııaktaılır. ilacın biı--likte kullanımı ilaç (etkileşimlerine sebep olabilir'. Bu. derlemenin amacı kardiyovasküler sistem hastalıklarında kullanılan ilaçlar ile enclo-- dontide sisteınik olaı--ak kullanılan ilaçlar arasın-- daki ilal; elkileşiıuleı'i üzerine bilgi sullıııakLır.

DRIIG INTERACTIONS RETWEEN DRUGS USED IN CARDIOVASCULAR SYSTEM DISEASES AND DRUGS USED IN ENDODONTIC TREATMENT SYST'EMATICALLY

During endodontic treatment various drugs could be prescribed to the patients with cardiovascular diseases. These prescribed ılımlı,-5 ıtnııld he used tngnther with the drugs which ha.-=. already used by the patient. Combined use of two drugs carı cause dı.—ug interactions as well as ether drug ı'eacLLUıısı 'l'lıe aim ul Lllis review i5 Lü pı'uvi— rle infrırmatien m1 drug interactions heh/verın drugs used in. cardiovascular system diseases and drugs used in endodontic treatment systemati— tally.

PDF

___

Arslan Sl, Atalay A, Kur.-2:11 V. Yaşlılarda ilaç: kullanımı. Geriatri 2000; 3: 56—60.
Ingle II. Glick DII. Different diagnusıs and treatnıerıt of dental pain. In: Ingle JI. Tain— lur FC Liz-Lis). ELLdULlunLics. [Sm eu), Phila— delphia, Lea Fnhifier 985; pp 288 289.
Classen DC, Pestctrıil-ı: SL, Evans RS, et al. Adverse drug event: in hospitalized pati— ents. Excess length of stay. extra costs. uml aLLI'ibulable Inurlelity. [AMA 1997; 2'77: 301 306.
Levy M, Kewitz H, Altw'ein W, et al. Hospi— tal admissions due to adverse drug reacti— ons: comparative study from Ierusalen‘i and Berlin. Eur] L'lili Plial'nluuul 198i); 1?: 25 31.
Schneexveiss S, Hasfortl I, Gottler M, e1: al. Admissions caused by adverse drug events to inLeL'nui [medicine and muer— geucy departnleuis in huspiiuls: a. lutlgiLu— riirml population halım-ri study. Eur Clin Pharmacol 2002; 58: 285—29
van der Ilooft CS. Stuı'kenlııoon'ı IMC. varı Gi'uuilieesl K. eL :11. Adverse drug reaction— related hospitalisation? nafinnwirln study in The Netherlands". Drug Saf 2006; 29: 161—168.
Fuhr U. Improvel‘nent in the handling of ıiı'uhılı'ııj—ııiıı1.(:ı':ıı:liıııı:ı'. Hur] [İliıı PlIHI‘IIIi-l col 2008: 64-: 167—171.
Delpöı'ı GCF. Fârrnacos antiarl‘itn'iicos. Eu: 'l‘auiargu ]. [_uuuı'd). Eunııauuiugiu Cal'— Liiuvasculai. Auuiün Niediua 2009; pp. 15— QR. Trujillo TC, Nolan PE. Antiarrhythmic agents: Drug interactions of clinical signi— ficance. Drug :iafZüUU; 2.5: SW —532.
Ynmrnudnnw‘nnfi W, dr: Risschnp M, Mar rin I.Ö. vr ;ııl. Pntm'ıtinlly :;igııii'irnnt ıl interactions of class III antiarrhythmic drugs. Drug Saf 2003; 2G: 421—438.
Singh BN. Vaughan W'illiauıs HM. third cins.-= (ıf anti arrhythmic action. Effects: on atrial and ventricular intracellular poten— tials, and other pharmacological actions on cardiac muscle. of MI 1999 and AII 3474-. BI‘IPhaL'Iuacul1970;39:675—687.
Cazznla M, Ringi F, En'ifi FL Antibiotic-I: and the Lung. European Respiratory Society Monograph [Pharmacological interactions behave-en antibiotics and other drugs in the Lı’ealıııeııL ul' luvver I'espiiuLui‘y LL'uul infections) 211045231229 2H4.
Rubinstein E. Comparative safety of the different macrolides. Int Antimicrob Agents 2001;18:571—576.
vuıı Ruseusteil NA, Admin 1). Nlacı'ulide anrihactcr‘inls. Drug interactions of elini :?:-ıl significance Drug Saf 1095: '13: 122.
Paar D. Teriung 13. Sauerbruch T. Life— llu‘eaLening inlel'auLiun LIeLweeIi ularilll— rnmycin anrl riisnpyrnmidn. Lancet 1997; 349: 326—327.
Henneman A, Thornby KA. Risk of hypo— tension with concomitant use of calcium— cliannel bluukers and iilaurulide auLibiU— tin-::. Am Health Syf:.r Phnr'm 2012: 69: 1038—1043.
“Wight A], Gornes T. Mamdaı'ıi Ml'VI. et al. The risk of hypotension following co— presuripiiuu ul inucruliLie unLiLıiulius and calcium channel blockers. CMA] 21111; 183: 303—307.
Jean—Pascal AS. Robert B. Stephane 0. et a.]. Nuu—sLeı-uidal uııLi—ırıflsımıı—ızıtory drug: [NSAIDS] and llypeL‘Leusiuu LreuLnleuL inrvnrfifirarinn: pnplllntiel based cohort study. Eur Clin Pharmacol 2012; 68: 1533—1540.
'.ı'Vull'l. K. HusLuıııi—Hudjegaıı A. Hay AW. eL a]. 'Pnnulafinn based pharmacnkine‘rir‘. apprnarh For methadone menirnring nF opiate addicts: potential Clinical utility. Addiction 2000;95:1771—1783.
Hı:ı'ı'|iıı K, Sı:r_ı:r'ıliı|ıl M, (in.—:lnlr—ihnn Ll], (:|. 31. Mcrhcıdcmc. clprofloxacln, and advers drug reactions. Lancet 2000; 356: 2069— 2070.
Laksluuau D, Siuıuıı C. Ursula C. eL al. Ad.— verse drug interactions: handbook for prescribers. Br Clin Pharmacol 2011; 71: 301—302.
Maurer PNl. Barlkuwski RR. Drug interac— Liuns ul clinical signiliuume wiLIı npi analgesics. Drug Saf1 993: R: 30 4Q.
Tokgöz M. Diş Hekimliği ve Sistemik Has— talıklar. Ecem Basım. İstanbul 2004: ss 456-
Riee P], Perry R], Afzal ?., nr al. Antihncte rial prescribing and “Parfarln: review. Br Dent 2003; 194: 411—415.
Conly ]. Stein K. Reduction of vitarı'ıirı K2 uouuenLl'uLiuus in lıuıııaıı liver associated with the ıı.-:F. ını'Fhr'nnrl spectrum antimiern bials. Clin Invest Med 1994: 17: 531—539.
Brom’n KED, Miller R. Interaction of penicillin—G and warr—Arin. Can IIosp Pharin 1979; 32: 18—19.
H'ylek EM. Oral anticnafiulantr. Pharmacn logic issues for use in the elderly. Clin Ge— riatr B‘Ied 2001: 17: 1—13.
Alpaslan C. Diş Mekin-iliğinde Sık Kullanl— [dıı İlaçlı-ıı“ BRC B:151I1:;Allkdru 2006: h.» ki?’,